Aphton Announces Closing of Igeneon Acquisition

Aphton, a biopharmaceutical company focused on the development of immunotherapies for the treatment of cancer, announced the formal completion of its acquisition of Igeneon AG, a biopharmaceutical company based in Vienna, Austria. Pursuant to the agreement, Igeneon equity holders will receive an aggregate of 21.5 million shares of Aphton common stock in exchange for 100 percent of the equity of Igeneon. Igeneon AG will become a wholly owned subsidiary of Aphton Corporation.

Yahoo News (http://biz.yahoo.com/bw/050324/245646_1.html)